Next Article in Journal
A Two-Dimensional Human Minilung System (Model) for Respiratory Syncytial Virus Infections
Next Article in Special Issue
Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research
Previous Article in Journal
Host Cell Restriction Factors that Limit Influenza A Infection
Previous Article in Special Issue
Two Distinct Clinical Courses of Human Cowpox, Germany, 2015
Open AccessArticle

Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant

1
Chemical, Biological & Radiological Division, Dstl Porton Down, Salisbury SP4 0JQ, UK
2
Animal Health Laboratory, Ministry for Primary Industries, Wallaceville, Upper Hutt 5140, New Zealand
3
Checkmate Pharmaceuticals, One Broadway, 14th Floor, Cambridge, MA 02142, USA
4
The Pirbright Institute, Pirbright GU24 0NF, UK
*
Author to whom correspondence should be addressed.
Viruses 2017, 9(12), 378; https://doi.org/10.3390/v9120378
Received: 17 November 2017 / Revised: 3 December 2017 / Accepted: 4 December 2017 / Published: 9 December 2017
(This article belongs to the Special Issue Smallpox and Emerging Zoonotic Orthopoxviruses: What Is Coming Next?)
Smallpox vaccination carries a high risk of adverse events in recipients with a variety of contra-indications for live vaccines. Although alternative non-replicating vaccines have been described in the form of replication-deficient vaccine viruses, DNA vaccines, and subunit vaccines, these are less efficacious than replicating vaccines in animal models. DNA and subunit vaccines in particular have not been shown to give equivalent protection to the traditional replicating smallpox vaccine. We show here that combinations of the orthopoxvirus A27, A33, B5 and L1 proteins give differing levels of protection when administered in different combinations with different adjuvants. In particular, the combination of B5 and A27 proteins adjuvanted with CpG oligodeoxynucleotides (ODN) gives a level of protection in mice that is equivalent to the Lister traditional vaccine in a lethal vaccinia virus challenge model. View Full-Text
Keywords: smallpox; vaccine; subunit; CpG smallpox; vaccine; subunit; CpG
Show Figures

Figure 1

MDPI and ACS Style

Reeman, S.; Gates, A.J.; Pulford, D.J.; Krieg, A.; Ulaeto, D.O. Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant. Viruses 2017, 9, 378.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop